Biotech | December 22, 2021
Piramal Pharma takes a minority stake in Yapan Bio
The investment in Yapan Bio allows Piramal Pharma Solutions to broaden its service offerings in the fast-growing biologics CDMO space
The investment in Yapan Bio allows Piramal Pharma Solutions to broaden its service offerings in the fast-growing biologics CDMO space
He has over 22 years of experience in pharmaceutical sales & business development
The new manufacturing facility will be built at a subsidiary of Adcock Ingram and will commence operation in March 23
Expertise in exosomes isolation and characterization will drive innovation in this field
Laurus Labs Limited has reported consolidated financial results for the period ended September 30, 2021
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
This new lyophilizer is equipped with systems to best protect high value Active Pharmaceutical Ingredients (APIs) and doubles the lyophilization capacity at the site
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
_256_384.jpg)
In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report
_256_384.jpg)
CLSA, a capital market and investment group organised an Investors’ Forum where five Indian pharma companies participated. Excerpts from the report
Subscribe To Our Newsletter & Stay Updated
